Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/dc31q371

EMERGING THERAPEUTIC INTERVENTION FOR CONTROLLING SARCOPENIA: AN UPDATED REVIEW

Mainak Sur[1], Meghana Dhanraj Bhalke Shewalkar[2], Aarti Gorakhnath kanchar[3], Sheetal Chhaya[4*]

[1]Founder and Chief Physiotherapist, Thera-Cure Advanced Physiotherapy Clinic, Shyamnagar, North 24 Pgs, West Bengal, India
[2]Consultant Nutritionist & Dietician, Meghna's Nutrition Centre, Chh. Sambhajinagar Aurangabad, Maharashtra, India.
[3]Assistant Professor, Community medicine, Sayali Charitable Trust's College of Homoeopathy & Hospital, Deogiri Valley, Maharashtra, India.
[4*]Professor and Head, Department of Nutrition and Dietetics,Parul Institute of Applied Sciences,Parul University, Vadodara.

***Corresponding author:** Sheetal Chhaya
*Professor and Head, Department of Nutrition and Dietetics,Parul Institute of Applied Sciences,Parul University, Vadodara.

Abstract
Sarcopenia, characterized by age-related loss of skeletal muscle mass and function, poses significant health challenges, especially in aging populations. This updated review explores emerging therapeutic interventions aimed at mitigating sarcopenia, focusing on recent advancements in pharmacological, nutritional, and exercise-based strategies. Novel approaches such as myostatin inhibitors, anabolic agents, and nutraceuticals, including protein supplements and omega-3 fatty acids, show promising results in enhancing muscle health. Additionally, resistance training remains a cornerstone in sarcopenia management, while innovations in combination therapies are gaining traction. The review highlights the importance of early detection, personalized treatment plans, and interdisciplinary efforts to address sarcopenia effectively, emphasizing the need for further clinical trials to validate the efficacy of these interventions.

Keywords: Sarcopenia, Muscle Atrophy, Pharmacological Interventions, Hormonal Therapy, Selective Androgen Receptor Modulators (SARMs), Myostatin Inhibitors, Anabolic Agents.

1. Introduction
Sarcopenia, characterized by the progressive loss of skeletal muscle mass, strength, and function with aging, has emerged as a significant public health concern due to its association with frailty, reduced quality of life, and increased risk of morbidity and mortality (Larsson et al., 2019). Despite its growing prevalence in aging populations, the understanding of sarcopenia's complex etiology, which involves factors such as inflammation, hormonal changes, mitochondrial dysfunction, and lifestyle, remains incomplete (Wiedmer et al., 2021). Recent advances in therapeutic interventions, including pharmacological agents, nutritional strategies, exercise regimens, and novel molecular targets, offer promising avenues for mitigating its impact (Xiao et al., 2024). This updated review explores these

emerging interventions, focusing on their mechanisms of action, clinical efficacy, and potential integration into multidisciplinary approaches to prevent and treat sarcopenia.

1.2 Pharmacological Interventions

Myostatin Inhibitors

Myostatin, a negative regulator of muscle growth, has been a prominent target for therapeutic intervention (Baig et al., 2022). Recent trials of myostatin inhibitors, such as bimagrumab, have shown promise in enhancing muscle mass and function. However, concerns regarding long-term safety and efficacy remain (Wetzlich et al., 2024).

Hormone Replacement Therapy

Hormonal therapies, including testosterone and growth hormone supplementation, have demonstrated mixed results (Brill et al., 2002). While testosterone improves muscle strength, its adverse effects, such as cardiovascular risks, limit widespread use. Emerging selective androgen receptor modulators (SARMs) offer a safer alternative, exhibiting anabolic effects with minimal side effects (Machek et al., 2020).

Anti-inflammatory Agents

Chronic inflammation is a key driver of sarcopenia. Anti-inflammatory agents, such as TNF-α inhibitors, have been investigated for their potential to preserve muscle function (Pan et al., 2021). Although preclinical studies are encouraging, large-scale clinical trials are needed.

Table No. 1 Summarizing pharmacological interventions for controlling sarcopenia based on updated reviews: (Yoshimura et al., 2017; De Spiegeleer et al., 2018; Cacciatore et al., 2024)

Class of Drug/Compound	Examples	Mechanism of Action	Clinical Evidence	Limitations/Side Effects
Hormonal Therapy	Testosterone, GH, IGF-1	Stimulates protein synthesis, enhances muscle mass and strength.	Evidence supports improved muscle mass; mixed results on functional outcomes.	Risk of cardiovascular events, prostate enlargement (testosterone); glucose intolerance.
Myostatin Inhibitors	Bimagrumab, Follistatin	Inhibits myostatin, a negative regulator of muscle growth.	Clinical trials show increased muscle mass; unclear impact on strength and function.	High cost; potential for off-target effects.
Selective Androgen Receptor Modulators (SARMs)	Ostarine, Enobosarm	Stimulates muscle growth while minimizing androgenic side effects on other tissues.	Evidence of muscle gain in older adults and those with cachexia.	Long-term safety unknown; potential cardiovascular risks.
Anti-inflammatory Drugs	NSAIDs, TNF-α inhibitors	Reduces inflammation, which can impair muscle repair and function.	Some benefits in muscle function in inflammatory conditions; limited data in aging.	Risk of gastrointestinal bleeding (NSAIDs); immunosuppression (biologics).

Anabolic Steroids	Oxandrolone, Nandrolone	Enhances protein synthesis and muscle mass.	Effective in increasing lean body mass; limited by significant adverse effects.	Liver toxicity, mood changes, cardiovascular risks.
β2-Adrenergic Agonists	Clenbuterol, Formoterol	Promotes muscle hypertrophy and reduces muscle protein breakdown.	Effective in animal models; human trials are limited.	Tachycardia, tremors, and long-term cardiac risks.
Amino Acid Supplements	Leucine, HMB (β-Hydroxy β-Methylbutyrate)	Stimulates mTOR pathway, promoting muscle protein synthesis.	Evidence supports improved muscle mass and function in older adults.	Effectiveness varies; may not replace the benefits of complete protein intake.
Vitamin D and Calcium	Vitamin D3, Calcium	Enhances calcium metabolism, which supports muscle contraction and strength.	Improved muscle strength in individuals with vitamin D deficiency.	Hypercalcemia with excessive supplementation.
Antioxidants	Vitamin E, N-acetylcysteine	Reduces oxidative stress, which is implicated in muscle degradation.	Limited evidence for significant muscle improvements.	Unclear dosing guidelines; excessive use may interfere with natural adaptive responses.
Metabolic Agents	Metformin, Resveratrol	Modulates pathways related to energy metabolism and inflammation.	Preliminary evidence suggests benefits in muscle function and reduction of fat mass.	Gastrointestinal side effects (metformin); limited human data (resveratrol).

1.3 Nutritional Strategies

Protein Supplementation

Adequate protein intake is essential for muscle protein synthesis. Studies recommend a daily intake of 1.2–1.6 g/kg of protein for older adults to counteract sarcopenia (Nowson and O'Connell, 2015). Leucine-enriched amino acid supplements have shown superior efficacy in promoting muscle anabolism (Park et al., 2024).

Omega-3 Fatty Acids

Omega-3 fatty acids exhibit anti-inflammatory properties and enhance muscle protein synthesis (Jeromson et al., 2015). Clinical trials have reported improvements in muscle strength and functional capacity with omega-3 supplementation (Krzymińska-Siemaszko et al., 2015).

Micronutrient Supplementation

Vitamin D and calcium are critical for musculoskeletal health. Deficiencies in these nutrients are prevalent among older adults and exacerbate sarcopenia (Zhang and Li, 2024). Supplementation has shown modest benefits in muscle strength and physical performance.

Table No. 2 Summarizing key points on Therapeutic Interventions for Controlling Sarcopenia

Category	Therapeutic Intervention	Mechanism of Action	Key Findings
Exercise	Resistance Training	Stimulates muscle hypertrophy, improves mitochondrial function, and increases protein synthesis (Porter et al., 2015).	Shown to significantly enhance muscle mass and strength in sarcopenic individuals.
	Aerobic Exercise	Improves oxidative capacity and reduces inflammation (Wang et al., 2021).	Complementary to resistance training, supports cardiovascular and muscular endurance.
Nutritional Strategies	Protein Supplementation	Enhances muscle protein synthesis through the mTOR signaling pathway (Ilha et al., 2018).	Optimal intake: ~1.2–1.5 g/kg/day, with leucine-rich proteins proving more effective.
	Vitamin D Supplementation	Supports muscle function by regulating calcium and phosphate metabolism (Boland, 1986).	Beneficial in sarcopenic older adults, especially those with vitamin D deficiency.
	Omega-3 Fatty Acids	Anti-inflammatory properties, enhance muscle protein synthesis (Tewari et al., 2020).	Promising results in reducing inflammation-related muscle loss.
Pharmacological Agents	Selective Androgen Receptor Modulators (SARMs)	Mimic anabolic effects of testosterone with minimal side effects (Rolland et al., 2011).	Early studies show improved muscle mass and strength; long-term safety under review.
	Myostatin Inhibitors	Block myostatin, a negative regulator of muscle growth.	Ongoing research; animal studies show significant muscle hypertrophy.
	Anti-inflammatory Drugs	Reduce chronic inflammation linked to sarcopenia (Allen, 2017).	Mixed results; further studies needed to evaluate efficacy and safety.
Hormonal Therapies	Growth Hormone and IGF-1 Therapy	Stimulates muscle growth and regeneration (Kraemer et al., 2017).	Limited by side effects; potential benefit in severe cases.
	Testosterone Replacement Therapy	Enhances muscle mass through androgenic effects (Sinclair et al., 2016).	Effective in testosterone-deficient individuals; risks include cardiovascular and prostate issues.
Regenerative Medicine	Stem Cell Therapy	Promotes muscle regeneration and repair (Qazi et al., 2019).	Preclinical studies promising; clinical applications still under investigation.

Lifestyle Modifications	Sleep Optimization	Enhances recovery and muscle protein synthesis (Res et al., 2012).	Poor sleep linked to increased risk of sarcopenia; improvements in sleep quality beneficial.
	Smoking Cessation	Reduces oxidative stress and systemic inflammation (Zuo et al., 2014).	Associated with reduced sarcopenia risk over time.
Emerging Approaches	Gut Microbiota Modulation	Links gut health to muscle function via the gut-muscle axis (Ticinesi et al., 2019).	Probiotics and prebiotics show potential in modulating inflammation and improving muscle health.
	Senolytics	Targets and clears senescent cells contributing to muscle aging (Englund et al., 2021).	Promising but requires more clinical evidence for safety and efficacy.

1.4 Exercise Interventions

Resistance Training

Resistance training is the cornerstone of sarcopenia management. Regular training improves muscle strength, mass, and functional outcomes. Novel modalities, such as blood flow restriction training, are gaining traction for their efficacy and reduced strain on joints (Cacciatore et al., 2024).

Aerobic Exercise

While resistance training is prioritized, aerobic exercise complements muscle health by improving cardiovascular fitness and reducing fat infiltration into muscles (Schumann et al., 2022).

1.5 Emerging Technologies

Gene Therapy

Gene therapy targeting myostatin and follistatin pathways holds potential for sarcopenia treatment. Preclinical models have demonstrated enhanced muscle growth and strength (Skrzypczak et al., 2021).

Tissue Engineering

Advances in bioengineering, including the development of muscle constructs using stem cells, offer promising avenues for muscle regeneration (Jiang et al., 2022).

Digital Health Tools

Wearable devices and telemedicine platforms facilitate real-time monitoring and personalized interventions for sarcopenia (Turimov Mustapoevich and Kim, 2023).

1.6 Physiotherapy against sarcopenia

Physiotherapy plays a crucial role in combating sarcopenia, a condition characterized by age-related loss of muscle mass, strength, and function (Billot et al., 2020). Through tailored exercise programs, physiotherapy helps improve muscle strength, enhance mobility, and restore functional independence (Turunen et al., 2017). Resistance training, a cornerstone of physiotherapy for sarcopenia, stimulates muscle protein synthesis and combats muscle atrophy (Zhang et al., 2024). Aerobic exercises and balance training further support cardiovascular health and reduce fall risks, enhancing overall quality of life. Physiotherapists also provide education on posture correction, injury prevention, and

ergonomic movements, empowering individuals to maintain an active lifestyle (Padhan and Mohapatra, 2023). When combined with proper nutrition and medical management, physiotherapy offers an effective, non-invasive approach to mitigating the impact of sarcopenia.

Table No. 3 Summarizing the role of physiotherapy in managing sarcopenia (Iversen et al., 2017; Joy et al., 2016):

Aspect	Description	Examples
Exercise Type	Resistance Training	Weightlifting, resistance bands, bodyweight exercises
	Aerobic Training	Walking, cycling, swimming
	Balance Training	Tai Chi, single-leg stands, balance boards
	Functional Training	Sit-to-stand exercises, stair climbing, carrying objects
Goals	Improve Muscle Strength	Enhance muscle fiber activation and prevent atrophy
	Enhance Mobility	Maintain joint flexibility and ease of movement
	Reduce Fall Risk	Improve coordination and stability
	Increase Functional Independence	Facilitate daily activities like standing, walking, and carrying
Techniques	Progressive Overload	Gradually increasing resistance or difficulty in exercises
	Posture Training	Exercises to correct and maintain proper body alignment
	Neuromuscular Re-education	Improving coordination and motor control
	Stretching	Maintaining muscle flexibility and range of motion
Additional Interventions	Education	Guidance on safe exercises, fall prevention, and activity planning
	Collaboration	Working with dietitians for nutritional support (e.g., protein intake)
	Technology Use	Utilizing tools like resistance machines or wearable sensors for tracking
Outcomes	Increased Muscle Mass	Stimulating muscle growth and repair
	Improved Quality of Life	Enhancing physical independence and confidence
	Prevention of Secondary Conditions	Reducing risks associated with immobility, such as osteoporosis

Advanced Physiotherapy Techniques

1. **Blood Flow Restriction (BFR) Training**

BFR training involves applying controlled pressure to a limb while performing low-intensity resistance exercises. This technique enhances muscle hypertrophy and strength with minimal joint stress, making it ideal for older adults with sarcopenia (Takarada et al., 2023).

2. **Electrical Muscle Stimulation (EMS)**

EMS involves the application of low-frequency electrical impulses to stimulate muscle contractions. Studies indicate that EMS can help maintain muscle mass and function in individuals with limited mobility (Paillard, 2018).

3. **Hydrotherapy**

Water-based exercises provide resistance with reduced joint impact, making them an effective method for strengthening muscles and improving balance in sarcopenic individuals (Becker, 2022).

Rehabilitation Protocols

1. **Stage-Wise Physiotherapy Approach**

Mild Sarcopenia: Focus on resistance training, functional exercises, and balance training.
Moderate Sarcopenia: Incorporate EMS, aquatic therapy, and progressive resistance exercises.
Severe Sarcopenia: Low impact strengthening exercises, neuromuscular re-education, and assistive device training.

2. **Case Studies and Evidence-Based Outcomes**

Case studies demonstrating improvements in muscle strength, mobility, and functional independence with structured physiotherapy programs.

Preventive Physiotherapy Strategies

1. **Workplace Ergonomics**

Encouraging proper posture, periodic stretching, and movement breaks to reduce the risk of muscle degeneration in desk-bound individuals.

2. **Home-Based Physiotherapy Programs**

Simple, structured exercises using resistance bands, body weight, and mobility drills to maintain muscle health at home (Liao et al., 2021).

Challenges and Future Directions

Despite significant progress, challenges persist in translating preclinical findings into clinical practice. Safety concerns, high costs, and variability in patient responses necessitate further research. Multidisciplinary approaches integrating pharmacology, nutrition, and physical therapy are essential for optimal outcomes.

Conclusion

Sarcopenia, a progressive loss of skeletal muscle mass and function, poses significant challenges to aging populations worldwide. Emerging therapeutic interventions highlight the importance of a multifaceted approach involving pharmacological, nutritional, and physical activity strategies. Advances in molecular biology have uncovered pathways, such as the myostatin/activin signalling axis, that hold promise for targeted therapies. Concurrently, the role of dietary supplements like protein, amino acids, and omega-3 fatty acids, combined with resistance training, has shown potential in mitigating muscle loss and promoting regeneration. While these developments are encouraging, further clinical trials are necessary to validate efficacy, optimize intervention protocols, and address individual variability. This updated review underscores the critical need for integrated therapeutic models to combat sarcopenia and enhance the quality of life in aging populations.

References

1. Allen, S. C. (2017). Systemic inflammation in the genesis of frailty and sarcopenia: an overview of the preventative and therapeutic role of exercise and the potential for drug treatments. Geriatrics, 2(1), 6.
2. Baig, M. H., Ahmad, K., Moon, J. S., Park, S. Y., Ho Lim, J., Chun, H. J., ... & Choi, I. (2022). Myostatin and its regulation: a comprehensive review of myostatin inhibiting strategies. Frontiers in physiology, 13, 876078.
3. Becker, B. E. (2022). Aquatic therapy: scientific foundations and clinical rehabilitation applications. PM&R, 14(1), 45-58.
4. Billot, M., Calvani, R., Urtamo, A., Sánchez-Sánchez, J. L., Ciccolari-Micaldi, C., Chang, M., ... & Freiberger, E. (2020). Preserving mobility in older adults with physical frailty and sarcopenia: opportunities, challenges, and recommendations for physical activity interventions. Clinical interventions in aging, 1675-1690.
5. Billot, M., Calvani, R., Urtamo, A., Sánchez-Sánchez, J. L., Ciccolari-Micaldi, C., Chang, M., ... & Freiberger, E. (2020). Preserving mobility in older adults with physical frailty and sarcopenia:

opportunities, challenges, and recommendations for physical activity interventions. Clinical Interventions in Aging, 1675-1690.
6. Boland, R. (1986). Role of vitamin D in skeletal muscle function. Endocrine reviews, 7(4), 434-448.
7. Brill, K. T., Weltman, A. L., Gentili, A., Patrie, J. T., Fryburg, D. A., Hanks, J. B., ... & Veldhuis, J. D. (2002). Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men. The Journal of Clinical Endocrinology & Metabolism, 87(12), 5649-5657.
8. Cacciatore, S., Calvani, R., Esposito, I., Massaro, C., Gava, G., Picca, A., ... & Landi, F. (2024). Emerging targets and treatments for sarcopenia: a narrative review. Nutrients, 16(19), 3271.
9. Cacciatore, S., Calvani, R., Esposito, I., Massaro, C., Gava, G., Picca, A., ... & Landi, F. (2024). Emerging targets and treatments for sarcopenia: a narrative review. Nutrients, 16(19), 3271.
10. De Spiegeleer, A., Beckwée, D., Bautmans, I., & Petrovic, M. (2018). Pharmacological interventions to improve muscle mass, muscle strength and physical performance in older people: an umbrella review of systematic reviews and meta-analyses. Drugs & aging, 35, 719-734.
11. Englund, D. A., Zhang, X., Aversa, Z., & LeBrasseur, N. K. (2021). Skeletal muscle aging, cellular senescence, and senotherapeutics: current knowledge and future directions. Mechanisms of ageing and development, 200, 111595.
12. Ilha, J., do Espírito-Santo, C. C., & de Freitas, G. R. (2018). mTOR signaling pathway and protein synthesis: from training to aging and muscle autophagy. Muscle Atrophy, 139-151.
13. Iversen, V. M., Mork, P. J., Vasseljen, O., Bergquist, R., & Fimland, M. S. (2017). Multiple-joint exercises using elastic resistance bands vs. conventional resistance-training equipment: A cross-over study. European journal of sport science, 17(8), 973-982.
14. Iversen, V. M., Mork, P. J., Vasseljen, O., Bergquist, R., & Fimland, M. S. (2017). Multiple-joint exercises using elastic resistance bands vs. conventional resistance-training equipment: A cross-over study. European Journal of Sport Science, 17(8), 973-982.
15. Jeromson, S., Gallagher, I. J., Galloway, S. D., & Hamilton, D. L. (2015). Omega-3 fatty acids and skeletal muscle health. Marine drugs, 13(11), 6977-7004.
16. Jiang, Y., Torun, T., Maffioletti, S. M., Serio, A., & Tedesco, F. S. (2022). Bioengineering human skeletal muscle models: Recent advances, current challenges and future perspectives. Experimental Cell Research, 416(2), 113133.
17. Joy, J. M., Lowery, R. P., de Souza, E. O., & Wilson, J. M. (2016). Elastic bands as a component of periodized resistance training. The Journal of Strength & Conditioning Research, 30(8), 2100-2106.
18. Joy, J. M., Lowery, R. P., de Souza, E. O., & Wilson, J. M. (2016). Elastic bands as a component of periodized resistance training. The Journal of Strength & Conditioning Research, 30(8), 2100-2106.
19. Kraemer, W. J., Ratamess, N. A., & Nindl, B. C. (2017). Recovery responses of testosterone, growth hormone, and IGF-1 after resistance exercise. Journal of Applied Physiology, 122(3), 549-558.
20. Krzymińska-Siemaszko, R., Czepulis, N., Lewandowicz, M., Zasadzka, E., Suwalska, A., Witowski, J., & Wieczorowska-Tobis, K. (2015). The effect of a 12-week omega-3 supplementation on body composition, muscle strength and physical performance in elderly individuals with decreased muscle mass. International journal of environmental research and public health, 12(9), 10558-10574.
21. Larsson, L., Degens, H., Li, M., Salviati, L., Lee, Y. I., Thompson, W., ... & Sandri, M. (2019). Sarcopenia: aging-related loss of muscle mass and function. Physiological reviews, 99(1), 427-511.
22. Liao, C. D., Tsauo, J. Y., Lin, L. F., Huang, S. W., Ku, J. W., Chou, L. C., & Liou, T. H. (2021). Effects of elastic band exercise on lean mass and physical function in older adults with

sarcopenia: A systematic review and meta-analysis of randomized controlled trials. Archives of Physical Medicine and Rehabilitation, 102(5), 944-959.
23. Machek, S. B., Cardaci, T. D., Wilburn, D. T., & Willoughby, D. S. (2020). Considerations, possible contraindications, and potential mechanisms for deleterious effect in recreational and athletic use of selective androgen receptor modulators (SARMs) in lieu of anabolic androgenic steroids: A narrative review. Steroids, 164, 108753.
24. Nowson, C., & O'Connell, S. (2015). Protein requirements and recommendations for older people: a review. Nutrients, 7(8), 6874-6899.
25. Padhan, S., & Mohapatra, A. (2023). Empowering Wellness: Unveiling the Key Role of Physiotherapy in Preventive and Promotive Health. Indian Journal of Preventive Medicine, 11(2).
26. Padhan, S., & Mohapatra, A. (2023). Empowering wellness: unveiling the key role of physiotherapy in preventive and promotive health. Indian Journal of Preventive Medicine, 11(2).
27. Paillard, T. (2018). Electrical stimulation-induced resistance training: an alternative way to maintain muscle strength and mass in aging. European Journal of Aging, 15(3), 193-201.
28. Pan, L., Xie, W., Fu, X., Lu, W., Jin, H., Lai, J., ... & Xiao, W. (2021). Inflammation and sarcopenia: a focus on circulating inflammatory cytokines. Experimental Gerontology, 154, 111544.
29. Park, S. J., Nam, C. H., Ahn, H. S., & Kim, T. (2024). The efficacy and safety of leucine-enriched essential amino acids in knee osteoarthritis patients: A randomized controlled trial. Medicine, 103(19), e38168.
30. Porter, C., Reidy, P. T., Bhattarai, N., Sidossis, L. S., & Rasmussen, B. B. (2015). Resistance exercise training alters mitochondrial function in human skeletal muscle. Medicine and science in sports and exercise, 47(9), 1922.
31. Qazi, T. H., Duda, G. N., Ort, M. J., Perka, C., Geissler, S., & Winkler, T. (2019). Cell therapy to improve regeneration of skeletal muscle injuries. Journal of cachexia, sarcopenia and muscle, 10(3), 501-516.
32. Res, P. T., Groen, B., Pennings, B., Beelen, M., Wallis, G. A., Gijsen, A. P., ... & van Loon, L. J. (2012). Protein ingestion before sleep improves postexercise overnight recovery. Medicine & Science in Sports & Exercise, 44(8), 1560-1569.
33. Rolland, Y., Onder, G., Morley, J. E., Gillette-Guyonet, S., van Kan, G. A., & Vellas, B. (2011). Current and future pharmacologic treatment of sarcopenia. Clinics in geriatric medicine, 27(3), 423-447.
34. Schumann, M., Feuerbacher, J. F., Sünkeler, M., Freitag, N., Rønnestad, B. R., Doma, K., & Lundberg, T. R. (2022). Compatibility of concurrent aerobic and strength training for skeletal muscle size and function: an updated systematic review and meta-analysis. Sports Medicine, 52(3), 601-612.
35. Sinclair, M., Grossmann, M., Hoermann, R., Angus, P. W., & Gow, P. J. (2016). Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: a randomised controlled trial. Journal of hepatology, 65(5), 906-913.
36. Skrzypczak, D., Skrzypczak-Zielińska, M., Ratajczak, A. E., Szymczak-Tomczak, A., Eder, P., Słomski, R., ... & Krela-Kaźmierczak, I. (2021). Myostatin and follistatin—new kids on the block in the diagnosis of sarcopenia in IBD and possible therapeutic implications. Biomedicines, 9(10), 1301.
37. Takarada, Y., Nakamura, Y., Aruga, S., Onda, T., Miyazaki, S., & Ishii, N. (2023). Rapid increase in plasma growth hormone after low-intensity resistance exercise with vascular occlusion. Journal of Applied Physiology, 88(1), 61-65.
38. Tewari, S., Ramkrishna, K. S., & Dhiman, T. (2020). A review on nutraceutical: the combination of nutrition and pharmaceutical. J Nutraceuticals Food Sci, 3(4), 1899-1906.
39. Ticinesi, A., Lauretani, F., Tana, C., Nouvenne, A., Ridolo, E., & Meschi, T. (2019). Exercise and immune system as modulators of intestinal microbiome: implications for the gut-muscle axis hypothesis. Exercise immunology review, 25.

40. Turimov Mustapoevich, D., & Kim, W. (2023, September). Machine learning applications in sarcopenia detection and management: A comprehensive survey. In Healthcare (Vol. 11, No. 18, p. 2483). MDPI.
41. Turunen, K., Aaltonen, L., Kumpumäki, J., Portegijs, E., Keikkala, S., Kinnunen, M. L., ... & Nikander, R. (2017). A tailored counseling and home-based rehabilitation program to increase physical activity and improve mobility among community-dwelling older people after hospitalization: protocol of a randomized controlled trial. BMC musculoskeletal disorders, 18, 1-10.
42. Turunen, K., Aaltonen, L., Kumpumäki, J., Portegijs, E., Keikkala, S., Kinnunen, M. L., ... & Nikander, R. (2017). A tailored counseling and home-based rehabilitation program to increase physical activity and improve mobility among community-dwelling older people after hospitalization: protocol of a randomized controlled trial. BMC Musculoskeletal Disorders, 18, 1-10.
43. Wang, X., Wang, Z., & Tang, D. (2021). Aerobic exercise alleviates inflammation, oxidative stress, and apoptosis in mice with chronic obstructive pulmonary disease. International journal of chronic obstructive pulmonary disease, 1369-1379.
44. Wetzlich, B., Nyakundi, B. B., & Yang, J. (2024). Therapeutic applications and challenges in myostatin inhibition for enhanced skeletal muscle mass and functions. Molecular and Cellular Biochemistry, 1-19.
45. Wiedmer, P., Jung, T., Castro, J. P., Pomatto, L. C., Sun, P. Y., Davies, K. J., & Grune, T. (2021). Sarcopenia–Molecular mechanisms and open questions. Ageing research reviews, 65, 101200.
46. Xiao, Y. L., Gong, Y., Qi, Y. J., Shao, Z. M., & Jiang, Y. Z. (2024). Effects of dietary intervention on human diseases: molecular mechanisms and therapeutic potential. Signal Transduction and Targeted Therapy, 9(1), 59.
47. Yoshimura, Y., Wakabayashi, H., Yamada, M., Kim, H., Harada, A., & Arai, H. (2017). Interventions for treating sarcopenia: a systematic review and meta-analysis of randomized controlled studies. Journal of the American Medical Directors Association, 18(6), 553-e1.
48. Zhang, F., & Li, W. (2024). Vitamin D and sarcopenia in the senior people: a review of mechanisms and comprehensive prevention and treatment strategies. Therapeutics and Clinical Risk Management, 577-595.
49. Zhang, N., Zhai, L., Wong, R. M. Y., Cui, C., Law, S. W., Chow, S. K. H., ... & Cheung, W. H. (2024). Harnessing immunomodulation to combat sarcopenia: current insights and possible approaches. Immunity & Ageing, 21(1), 55.
50. Zhang, N., Zhai, L., Wong, R. M. Y., Cui, C., Law, S. W., Chow, S. K. H., ... & Cheung, W. H. (2024). Harnessing immunomodulation to combat sarcopenia: current insights and possible approaches. Immunity & Ageing, 21(1), 55.
51. Zuo, L., He, F., Sergakis, G. G., Koozehchian, M. S., Stimpfl, J. N., Rong, Y., ... & Best, T. M. (2014). Interrelated role of cigarette smoking, oxidative stress, and immune response in COPD and corresponding treatments. American Journal of Physiology-Lung Cellular and Molecular Physiology, 307(3), L205-L218.